Eli Lilly and Company (LLY) reported a very strong start to 2025, characterized by significant revenue growth primarily driven by its incretin portfolio (Mounjaro and Zepbound). This substantial top-line growth translated into notable increases in earnings per share (EPS), even after absorbing significant acquired in-process research and development (IPR&D) charges related to strategic pipeline investments. The company highlighted positive developments in its late-stage pipeline, particularly for an oral diabetes treatment, and confidently reaffirmed its full-year financial outlook.
Key Financial Highlights
- Revenue: Total revenue reached $12.73 billion, a robust 45% increase compared to Q1 2024. This growth signifies strong market uptake and demand for Lilly’s key products.
- Growth Drivers: The primary engine for this growth was the exceptional performance of Mounjaro for type 2 diabetes and Zepbound for chronic weight management. While specific figures for each weren’t in the initial summary, their combined contribution was the main factor behind the 45% revenue jump.
Pipeline Developments
Orforglipron
Eli Lilly highlighted positive top-line results from Phase 3 clinical trials evaluating orforglipron. Orforglipron is an investigational, oral, non-peptide GLP-1 receptor agonist. This is significant because current widely-used GLP-1 agonists (like Mounjaro/Zepbound) are injectable.
Revenue
Expected to be in the range of $58.0 billion to $61.0 billion. Reaffirming this guidance despite the strong Q1 suggests confidence in sustained growth throughout the year, likely driven by continued Mounjaro and Zepbound momentum and other product contributions.
Last Modified:
